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Abstract
Citramalic acid is a central intermediate in a combined biocatalytic and chemocatalytic route to produce bio-based
methylmethacrylate, the monomer used to manufacture Perspex and other high performance materials. We developed an
engineered E. coli strain and a fed-batch bioprocess to produce citramalate at concentrations in excess of 80 g l 1 in only
65 h. This exceptional efficiency was achieved by designing the production strain and the fermentation system to operate
synergistically. Thus, a single gene encoding a mesophilic variant of citramalate synthase from Methanococcus jannaschii,
CimA3.7, was expressed in E. coli to convert acetyl-CoA and pyruvate to citramalate, and the ldhA and pflB genes were
deleted. By using a bioprocess with a continuous, growth-limiting feed of glucose, these simple interventions diverted
substrate flux directly from central metabolism towards formation of citramalate, without problematic accumulation of
acetate. Furthermore, the nutritional requirements of the production strain could be satisfied through the use of a mineral
salts medium supplemented only with glucose (172 g l 1 in total) and 1.4 g l 1 yeast extract. Using this system, citramalate
accumulated to 82±1.5 g l 1, with a productivity of 1.85 g l 1 h 1 and a conversion efficiency of 0.48 gcitramalate g
 1
glucose. The
new bioprocess forms a practical first step for integrated bio- and chemocatalytic production of methylmethacrylate.
INTRODUCTION
Methylmethacrylate (MMA) is used as the monomer to
manufacture polymethylmethacrylate, a transparent, bio-
compatible material, better known as Perspex and Lucite.
MMA is currently manufactured from petrochemical feed-
stocks, but is also an attractive target for more sustainable
bio-production due to the favourable price (£1400/tonne
[1]) and the large global market (2.1million tonnes [2]).
Despite numerous patent applications [3–5] on direct bio-
production of methacrylic acid (MAA), a precursor for
MMA, none of the proposed bioprocesses have yet been
translated into a manufacturing process. The key problems
hindering bio-production are (a) lack of enzymes to catalyse
direct formation of MMA or MAA from bio-based feed-
stocks and (b) the toxicity of both compounds and their
intracellular metabolites, due to their lipophilicity and reac-
tivity with cellular components [6]. Similar problems with
product toxicity are encountered commonly throughout the
bio-economy [7–9] and solutions are needed. For these rea-
sons, we investigated a combined bio- and chemocatalytic
route, as an alternative to direct bio-production of MMA or
MAA.
A facile, chemocatalytic route has already been developed
to convert mixtures of naturally occurring, bio-derived di-
and tricarboxylic acids to MAA in hot, pressurized water
[10, 11]. Suitable acids include citric, itaconic, mesaconic,
citraconic and citramalic acids [10, 11], and preliminary
economic analyses, coupled with enzyme screening, indi-
cated that citramalic acid was the most suitable target for
bio-production (Lucite International, personal communica-
tion). Preliminary work also showed that citramalate was
relatively non-toxic towards the host strain, since toxicity
tests showed that the EC50 for citramalate towards E. coli
was 173±7mM (25.6±1 g l 1) compared with 13.2±1.7mM
(1.1±0.1 g l 1) for MAA (Table S1, available in the online
Supplementary Material). Therefore, we developed citra-
malic acid production as the initial biocatalytic step in the
integrated bio- and chemocatalytic process. An E. coli
strain was engineered to produce citramalate from glucose,
by using citramalate synthase to catalyse the formation of
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citramalate from pyruvate and acetyl-CoA (Fig. 1) [12, 13],
and a fed-batch bioprocess was also developed. Our patent
describing this work was filed in 2014 and published in
2015 [14].
Since then, other workers have described a less efficient pro-
cess, again using citramalate synthase, but also using multi-
ple gene deletions (gltA leuC ackA-pta poxB) to control
acetate formation [15, 16]. These interventions were
required, because the fermentation strategy adopted
(repeated fed-batch culture with excess glucose [15, 16]) is
known to promote acetate formation by E. coli [17]. How-
ever, the use of multiple knockouts to control acetate and
citraconate formation resulted in a double auxotroph,
dependent upon addition of glutamate (5 g l 1) and leucine
(1 g l 1) to obtain cell growth [15, 16]. In the repeated fed-
batch system, a total of 110 g l 1 glucose, 25 g l 1 glutamate
and 5 g l 1 leucine were needed to obtain 54.1 g l 1 citrama-
late, produced over 87 h, and acetate production (1.4 g l 1)
was still observed, despite the deletions [16]. Unfortunately,
however, the addition of glutamate and leucine almost
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Webb et al., Microbiology
2
doubles the feedstock costs compared with a process using
glucose alone (based on current prices; Table S2). Although
these expensive supplements could be replaced with pep-
tone (15 g l 1), this strategy caused a decrease in product
concentration to 46.5 g l 1 [15], and still increased the feed-
stock costs by 31% compared with using glucose only
(Table S2). Furthermore, the product stream contained both
acetate and multiple organic contaminants from the pep-
tone, thus adding to the costs of product recovery and efflu-
ent treatment. Therefore, we considered it timely to publish
details of our patented production strain and fermentation
process, since we obtained citramalate production to con-
centrations of >80 g l 1 in only 65 h [14]. Acetate was not
produced, and a simple, low cost, mineral salts medium
could be used, containing only glucose and 1.4 g l 1 yeast
extract (<1% of the feedstock cost).
METHODS
Media and growth
Working stock cultures of E. coli strains were grown in LB,
and stored as glycerol stocks (10%w/v) at  80

C. Where
required, carbenicillin (50 µgml 1) and/or chloramphenicol
(34 µgml 1) were added to media. All small-scale cultures
in liquid media were grown at 37

C, with orbital shaking at
250 r.p.m., in baffled shake flasks.
SM medium [1 l [18]] contained glycerol (30ml; 500 g l 1),
yeast extract (50ml; 100 g l 1), MgSO4 (2ml; 246.47 g l
 1),
salt solution (200ml) containing Na2HPO4.12H2O (75.6 g
l 1), KH2PO4 (15 g l
 1), NH4Cl (5 g l
 1), NaCl (2.5 g l 1),
CaCl2 (55mg l
 1), and 100 µl of SM trace element solution
containing FeSO4.7H2O (80 l
 1 g), AlCl3.6H2O (10 g l
 1),
MnSO4.H2O (10 g l
 1), CoCl2 (4 g l
 1), ZnSO4.7H2O (2 g
l 1), Na2MoO4.2H2O (2 g l
 1), CuCl2.2H2O (1 g l
 1) and
H3BO3 (0.5 g l
 1) dissolved in HCl (3 M). Glycerol, yeast
extract, MgSO4.7H2O and salt solutions were prepared and
autoclaved separately, and trace elements were sterilized by
filtration using 0.2 µm, sterile filters. All solutions were
mixed when cooled.
Fermentation medium (1 l) contained glucose (100ml;
119 g l 1), MgSO4.7H2O (2ml; 246.47 g l
 1), polypropylene
glycol (0.1ml), salt solution (200ml) containing K2HPO4
(73 g l 1), NaH2PO4.2H2O (18 g l
 1), (NH4)2SO4 (10 g l
 1),
ammonium citrate (2.5 g l 1), and 2ml of fermentation
trace elements containing Na2EDTA.2H2O (22.3 g l
 1),
FeCl3 (10.03 g l
 1), CaCl2.2H2O (0.5 g l
 1), ZnSO4.7H2O
(0.18 g l 1), CoCl2.6H2O (0.18 g l
 1), CuSO4.5H2O (0.16 g
l 1) and MnSO4.H2O (0.15 g l
 1).
Strain construction
Restriction digestions, transformations, SDS-PAGE and
other standard molecular biological techniques, were per-
formed using common procedures [19]. PCR was per-
formed with KOD Hot Start Polymerase (Novagen) using
standard protocols.
E. coli BW25113DldhA :: camR was obtained from the Coli
Genetic Stock Centre [20] and pflB was also deleted from the
chromosome by l red-mediated recombination [21] to
produce E. coli BW25113DldhADpflB. The knockout resistance
cassette was obtained by using pKD4 as the template DNA
and the primers 5¢-ACGCAGTAAATAAAAAATCCACT-
TAAGAAGGTAGGTGTTACGTGTAGGCTGGAGCTGCT
TC-3¢ and 5¢-AGCCTTTATTGTACGCTTTTTACTGTAC-
GATTTCAGTCAAATCTAAATGGGAATTAGCCATGGT
CC-3¢. The antibiotic resistance cassettes were cured by using
the temperature sensitive plasmid pCP20 as described previ-
ously [21].
To produce pET20b(+)-mjcimA3.7, the cimA3.7 gene [12],
flanked by 5¢ NdeI and 3¢ NotI sites, was codon optimized
for expression in E. coli, synthesized de novo (Biomatik) and
ligated into pET20b(+) using standard techniques. The plas-
mid was transformed into E. coli BL21 (DE3)plysS to give
the strain E. coli BL21 (DE3)plysS pET20b(+)-mjcimA3.7.
To produce pBAD24-mjcimA3.7, the cimA3.7 gene was
amplified from the cloning vector, pBMH-mjcimA3.7,
using the primers 5¢-AAAGCTAGCAGGAGGAATTCAC-
CATGATGGTTCGTATCTTCG-3¢ and 5¢-TTTAAGCTT-
TACAGTTTACCAGTAACCTCACGC-3¢ to introduce a
5¢ NheI and 3¢ HindIII restriction site. The gene was
ligated into pBAD24 [22] and transformed into E. coli
BW25113DldhADpflB to give the strain E. coli
BW25113DldhADpflB pBAD24-mjcimA3.7, referred to as
E. coli JW1.
Citramalate production using harvested cells
Glycerol stocks of E. coli JW1 were used to inoculate SM
glycerol medium (200ml) to an OD600nm 0.025. The culture
was grown until the OD600nm reached 0.6, and CimA3.7
expression was induced by the addition of L-arabinose (0.2 g
l 1). Cells were harvested by centrifugation (4000 g, 20min,
4

C) at an OD600nm 3–4 and concentrated to a dry cell
weight of 15 g l 1 in SM medium without NH4Cl or yeast
extract, with glucose (20 g l 1) as the substrate. The cell sus-
pensions (approximately 20ml) were incubated in baffled
flasks (500ml) for 24 h at 250 r.p.m. and 37

C.
Citramalate synthase assay
Cell-free extracts of E. coli BL21 (DE3)plysS pET20b(+)-
mjcimA3.7 were prepared from cultures grown in LB
medium (200ml) 4 h after induction with IPTG (1mM).
Cells were harvested by centrifugation (4000 g, 20min, 4

C)
and resuspended in N-tris(hydroxyl)methyl-2-aminoetha-
nesulfonic acid buffer (TES; 0.1 M, pH 7.5, 6ml) containing
MgCl2 (5mM). Cells were lysed using a constant cell dis-
rupter by two passages at 20 000 psi. CimA3.7 was partially
purified by heating (60

C, 10min) and precipitated proteins
were removed by centrifugation (12 000 g, 10min). The
resulting cell-free extract was filtered (0.2 µm filter) and
diluted to 1 mg ml 1 protein in TES buffer (0.1M pH 7.5).
CimA3.7 was assayed using a modified method [13]. The
assay mixture (1ml) contained: acetyl-CoA (1mM), pyru-
vate (1mM), partially purified CimA3.7 (1 mg ml 1; 200 µl)
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and TES buffer (0.1 M, pH 7.5) containing MgCl2 (5mM).
The reaction mixture was incubated at 37

C and at regular
intervals (10min) samples (100 µl) were taken, mixed with
5,5¢-dithio-bis-(2-nitrobenzoic acid) (0.56mM), in Tris-HCl
buffer (78mM, pH 8; 900 µl), and the absorbance at 412 nm
measured.
Fed-batch fermentation
Inocula for fed-batch fermentations were developed by
inoculating glycerol stocks (20 µl) of E. coli JW1 into fer-
mentation medium (100ml) and incubating overnight. The
cultures were used to inoculate fermentation medium (3 l)
in a Fermac 360 bioreactor (Electrolab; 5 l vessel). Cultures
were grown at 37

C, and the pH was maintained at pH 7.0
by automated addition of acid and base. The air flow rate
was 3 lmin 1 and the dO2 was maintained at 30% of satura-
tion by automatic control of the stirrer speed between 600–
1200 r.p.m. A feed of glucose was started when the glucose
had been consumed, as indicated by a sharp increase in dO2
and confirmed using glucose oxidase test strips. The flow
rate was adjusted manually as required to maintain a
pseudo-exponential growth rate of approximately 0.25 h 1
and avoid the accumulation of excess glucose in the culture,
using the test strips as confirmation as above. CimA3.7
expression was induced by the addition of L-arabinose (0.2 g
l 1). Feed regimes thereafter are described in the text.
Analytical methods
Growth was monitored by measuring OD600nm. The sam-
ples were diluted in deionized water when the OD600nm was
>0.8. Dry cell weight was measured by centrifuging 1ml
samples in pre-weighed polypropylene tubes, removing the
supernatant and drying the pellets at 80

C to a constant
weight. Samples were prepared for high-performance liquid
chromatography (HPLC) analysis by boiling to inactivate
the biocatalyst, centrifuging (12 000 g, 5min) and filtering
the supernatants (0.45 µm filter). Samples (500 µl) were ana-
lysed using an Agilent 1200 series HPLC system with both
UV (210 nm) and refractive index detectors, using a Rezex
ROA Organic Acid H+column at 55

C with 5mM H2SO4
(0.5ml min 1) as the mobile phase. Products were identi-
fied by comparing the retention times with authentic, com-
mercial standards, and concentrations were determined
from calibration curves.
RESULTS
Design and construction of a citramalate-producing
E. coli strain
We considered a number of options for citramalate produc-
tion. Proof of concept for production of citramalate has
already been obtained using itaconate [23] or citraconate
[24] as the substrate for small-scale bioprocesses using har-
vested cells. However, the citraconate must be synthesized
by the thermal decomposition of citric acid [10, 25, 26],
which in turn needs to be produced by fermentation [27],
increasing the cost. Similarly, itaconate is produced either
by direct fermentation [28], or from citric acid as above [25,
26]. Furthermore, the growth and preparation of the har-
vested cells requires multiple unit operations, adding to pro-
cess complexity and cost. Therefore, we designed a simpler,
single-step fermentation of glucose directly to citramalate,
using metabolically engineered E. coli cells [14]. The best
characterized enzyme catalysing citramalate production is
citramalate synthase (CimA; EC 2.3.1.182) from the ther-
mophilic archeon, Methanococcus jannaschii [12, 13], which
utilizes pyruvate and acetyl-CoA as the substrates. Since the
latter metabolites are central metabolic intermediates, it
should be possible to obtain citramalate production from
glucose simply by expressing CimA in E. coli (Fig. 1 [14]).
Since wild-type CimA is most active at high temperatures
(e.g. 70

C [13]), we expressed a mesophilic variant,
CimA3.7, which was obtained by directed evolution [12].
The mutant enzyme contains five amino acid substitutions
and is truncated at the C-terminal, resulting in higher activ-
ity at mesophilic temperatures and resistance to isoleucine
feedback inhibition. This variant was used previously in
multi-step, engineered pathways to produce 1-butanol and
1-propanol [12], indicating its suitability for bio-based
chemical manufacturing.
Although CimA3.7 is active at 30

C [12], our process was
designed to operate at 37

C, the optimum growth tempera-
ture for E. coli. Therefore, we tested the activity of CimA3.7
at this higher temperature. The cimA3.7 gene was codon
optimized for expression in E. coli, cloned into pET20b(+),
and CimA activity was confirmed at 37

C (Fig. S1). No
activity was detected in control reactions lacking pyruvate
or using cell-free extracts from a strain containing an empty
pET20b(+) vector.
Expression of CimA3.7 from the T7 promoter of pET20b(+)
resulted in a large proportion being expressed as insoluble
protein (Fig. S2), which was unlikely to be active in vivo. To
overcome this, the cimA3.7 gene was cloned into pBAD24
[22] to produce pBAD24-mjcimA3.7, with CimA3.7 expres-
sion under the control of the arabinose-inducible, araBAD
promoter, to provide better control of expression levels.
Expression tests with varying L-arabinose concentrations
(Fig. S3) showed that maximum production of soluble
CimA3.7 was observed when cultures were induced with
0.2 g l 1 L-arabinose, with little formation of insoluble pro-
tein. Therefore, 0.2 g l 1 L-arabinose was used to induce
CimA3.7 expression in subsequent experiments.
The production strain was then designed, based on the
anticipated process configuration for industrial citramalate
production. Although E. coli is an excellent host for heterol-
ogous expression of engineered metabolic pathways, and
grows rapidly in minimal media, industrial fermentations
are frequently plagued by unproductive conversion of glu-
cose to acetic acid [17]. This decreases product yields and
also causes inhibition of cell growth [29]. However, robust
solutions to this problem are well known. By operating the
fermentations as fed-batch cultures with a continuous,
growth-limiting feed of glucose, acetate production can be
avoided completely [30]. Therefore, we considered that any
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further metabolic engineering, beyond the overexpression of
CimA3.7, could be minimized, and that there was no need
to delete any of the genes that are known to be involved in
acetate production. In addition to this, there was no need to
delete either leuC or leuD [15], even though 3-isopropylma-
late dehydratase is known to catalyse the conversion of cit-
ramalate to citraconate [12, 30–32]. Citraconate is a very
good substrate for the hot, pressurized water process to pro-
duce MAA [10, 11], and, therefore, we considered that any
formation of citraconate as a co-product alongside citrama-
late would be beneficial rather than detrimental (vide infra).
However, industrial fed-batch cultures have to be operated
at high biomass concentrations (>50 g l 1 dry weight),
which can lead to oxygen-limited microenvironments, even
within very well-mixed, high intensity fermentations [33].
Under oxygen limitation, E. coli switches to fermentative
metabolism, with wasteful formation of fermentation prod-
ucts from pyruvate. Therefore, lactate dehydrogenase and
pyruvate formate lyase were deleted to produce E. coli
BW25113DldhADpflB, to prevent unproductive pyruvate
metabolism [34], and thus maximize citramalate yields and
simplify product recovery. E. coli BW25113DldhADpflB was
then transformed with pBAD24-mjcimA3.7 to produce
E. coli JW1.
The production of citramalate from glucose was confirmed
by using E. coli JW1 in small-scale biotransformations,
and compared with wild-type E. coli BW25113 and
E. coli BW25113DldhA, both transformed with pBAD24-
mjcimA3.7, to assess the impact of the deletions on aerobic
growth and product formation (Table 1). Pre-induced, har-
vested cells were used in these tests to avoid induction of
enzymes involved in acetate formation, and thus obtain an
accurate comparison of product formation by the different
strains.
After 24 h, the glucose had been consumed by E. coli JW1
and converted to citramalate (7.7±0.3 g l 1), a yield of 0.39
±0.01 gcitramalate g
 1
glucose (0.47±0.01mol mol
 1). No other
organic acid contaminants (including acetate) were
detected. This suggested that glucose was converted to citra-
malate and CO2 as the sole products. A control strain con-
taining pBAD24 without mjcimA3.7 also consumed the
same amount of glucose but produced acetate as the sole
metabolic product (3.5±0.8 g l 1). Therefore, E. coli JW1
could produce significant quantities of citramalate, and
expression of CimA3.7 was sufficient to divert the C-flux
away from acetate production and towards citramalate for-
mation in the harvested, nitrogen-starved cells.
Wild-type E. coli BW25113 and E. coli BW25113 DldhA
(without the pflB knockout), both containing pBAD24-
mjcimA3.7, produced similar concentrations and yields of
citramalate as strain JW1, showing that neither of the
knockouts had detrimental effects on product formation
under aerobic biotransformation conditions in shake flasks.
Development of a bioprocess for production of
citramalate
A fed-batch bioprocess was developed at 3 l scale, to investi-
gate the scope for high productivity citramalate production.
E. coli JW1 was grown initially with excess glucose (11.9 g
l 1), until all the glucose had been consumed (Fig. 2; point
1). A concentrated glucose feed was then started, with step-
wise increases in the flowrate to maintain both pseudo-
exponential growth and glucose limitation, to avoid acetate
accumulation and consequent growth inhibition [17, 35].
After 21 h, when the OD was 50, L-arabinose (0.2 g l 1) was
added to induce synthesis of CimA3.7. Citramalate produc-
tion was detected almost immediately after induction
(Fig. 2; point 2), and continued at a rate of 1.6 g l 1 h 1,
even though growth slowed and had almost stopped after
22 h. Despite this decrease in growth rate, glucose consump-
tion continued, so that, after 39 h, a total of 365 g of glucose
had been consumed and converted to 111 g of citramalate
(29.5 g l 1), a yield of 0.30 gcitramalate g
 1
glucose (0.37mol
mol 1). It should be noted that the culture medium con-
tained only small quantities of yeast extract (only 0.85 g
l 1). Since this represented <1% of the total carbon-
containing substrates added to the fermentation, the yeast
extract had negligible effects on the calculated product
yields.
Small quantities of citraconate (6 g; 1.61 g l 1) were also
formed, presumably through dehydration of citramalate,
catalysed by 3-isopropylmalate dehydratase [12, 30–32]. As
noted above, this minor co-product can be tolerated since
citraconate is converted to MAA alongside citramalic acid
in the downstream chemical process [10, 11].
To test the potential of the non-growing cells to continue
forming citramalate, the feed was stopped (Fig. 2; point 3),
and a batch of glucose (120 g in total, 32 g l 1) was added to
the bioreactor as a concentrated solution in water. The glu-
cose was consumed within 8 h and converted to 25 g (7.5 g
l 1) citramalate. Pyruvate (43 g; 11.25 g l 1) accumulated
during the first 6 h after glucose addition, but the pyruvate
was re-consumed once the glucose had been fully utilized.
Surprisingly [17], acetate did not accumulate, despite the
Table 1. Citramalate production in small-scale biotransformations.
Strains were grown and induced in SM medium (200ml) with glycerol
as the carbon source, to avoid glucose catabolite repression of the
araBAD promoter. The cells were then harvested and resuspended to
15 g l 1 dry weight in fresh SM medium containing glucose (20 g l 1)
but without yeast extract or NH4Cl. Results are an average of triplicate
experiments and the error is the SD. ND, none detected.
Strain Glucose
consumed
(g l 1)
Citramalate
produced
(g l 1)
Acetate
produced
(g l 1)
E. coli JW1 19.9±0.4 7.7±0.3 ND
E. coli BW25113
DldhADpflB pBAD24
17.9±0.3 ND 3.5±0.8
E. coli BW25113 DldhA
pBAD24-mjcimA3.7
18.1±0.2 7.4±0.5 ND
E. coli BW25113 pBAD24-
mjcimA3.7
17.9±0.2 8.1±0.3 ND
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excess glucose present in the culture, presumably because
any acetyl-CoA formed from glucose was consumed effi-
ciently by the citramalate synthase reaction rather than
being converted to acetate. There was no further increase in
citraconate concentration and no further growth, indicating
that the glucose was used only for citramalate production.
After the glucose had been consumed, the concentration of
citramalate began to fall, so there was no benefit in pro-
longed incubation.
Overall, the maximum titre of citramalate observed was
168 g (44 g l 1), produced from 509 g glucose in 63 h,
including both the glucose used for cell growth and for cit-
ramalate production. Thus, the overall yield was 0.33 gcitra-
malate g
 1
glucose (0.40mol mol
 1). During the production
phase (i.e. after induction of CimA3.7), 383 g glucose was
added to produce 168 g citramalate, and only 42 g biomass
which indicates that 11% of the total glucose added was
used for biomass production and 44% for citramalate pro-
duction. The remaining carbon was lost as CO2 as a conse-
quence of energy generation via the TCA cycle and aerobic
respiration.
A further test of metabolic activity was made by harvesting
a sample of cells after 63 h and resuspending the cells in SM
biotransformation medium with 20 g l 1 glucose. After 24 h,
all of the glucose (20.5±0.06 g l 1) had been consumed and
13.5±0.3 g l 1 citramalate produced, a yield of 0.66±0.02 gci-
itramalate g
 1
glucose (0.8mol mol
 1). It should be noted that
this apparently high yield value does not include the glucose
utilized for cell growth, prior to harvesting from the culture,
which must also be taken into account to give the overall
yield across the whole bioprocess. A small amount of acetate
(1.14±0.09 g l 1) was also produced.
Since the cells maintained metabolic activity even after the
sustained period of starvation encountered at the end of this
fermentation, the bioprocess was modified to provide a con-
tinuous glucose feed throughout the production phase. The
initial stages of the bioprocess (Fig. 3) were operated in
exactly the same way as the process shown in Fig. 2, with a
continuous glucose feed started at point 1 and arabinose
induction at point 2. The glucose feed was continued for 4 h
after induction, to point 3, and then the feed rate was
adjusted as required to maintain a linear rate of citramalate
production. The required feed rate was estimated based on
the previous glucose consumption and citramalate produc-
tion rates (Fig. 2). The new bioprocess was repeated three
times, and the mean data for these fermentations are
reported (Fig. 3).
Once induced, citramalate production continued at a pro-
ductivity of 1.85±0.02 g l 1 h 1, slightly higher than in the
previous fed-batch fermentation (Fig. 2) and increased by
56% compared with the addition of a single batch of excess
glucose to stationary phase cells (Fig. 2). This shows that the
use of a continuous, limiting glucose feed enhances citrama-
late production compared with a discontinuous fed-batch
process, where the glucose is fed by adding batches of excess
glucose.
The fermentations were terminated after 65 h, due to our
limited capacity for shift work. Overall, 82±1.5 g l 1 of citra-
malate was produced from 172±11 g l 1 of glucose con-
sumed, a yield of 0.48±0.03 gcitramalate gglucose
 1 (0.58±0.03mol
Fig. 2. Fermentation for the production of citramalate. E. coli JW1 was
grown with glucose (11.9 g l 1) until all the glucose had been con-
sumed (point 1). A continuous, concentrated glucose feed was then
started, with stepwise increases in the flowrate whilst maintaining
glucose limitation. CimA3.7 expression was induced by adding L-arabi-
nose (0.2 g l 1; point 2). The glucose feed was maintained for a further
19 h at a constant rate. The feed was then switched off (point 3) and a
batch of glucose was added to the fermenter (120 g in total, 32 g l 1;
1 g l 1 gDCW 1 biomass). .–OD600nm, &–dry cell weight, ~–glucose
measured, !–glucose consumed, ¤-acetate, ○–pyruvate, □–citrama-
late,–citraconate.
Fig. 3. Citramalate production using a continuous glucose feed. Tripli-
cate fermentations of E. coli JW1 were established as in Fig. 1, with
the same glucose feeds to point 1 and 2. After induction with arabi-
nose (point 2), the glucose feed rate was the same as Fig. 1 for the
first 4 h. Thereafter (point 3), the feed rate was adjusted to deliver the
correct ratio of glucose: cell dry weight to maintain a linear rate of
product formation, based on rates measured in previous experiments.
Residual glucose could not be detected. Data are the means of tripli-
cate fermentations and the error bars indicate the SD. .–OD600nm, &–
dry cell weight,!–glucose consumed, □–citramalate.
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mol 1). Therefore, the use of a continuous glucose feed had
improved the overall titre and yield of citramalate by almost
twofold compared with batch-wise glucose addition (Fig. 2).
As before (Fig. 2), small quantities of citraconic acid (1.9
±0.3 g l 1) were also produced, which further emphasizes
that this is a minor co-product. Therefore, we conclude that
it is not necessary to delete leuC and/or leuD.
The reproducibility of the process was excellent across the
three replicate fermentations. Although the fermentations
were terminated after 65 h for practical reasons, there is
scope to continue the fermentations for longer periods to
explore the possibility of obtaining higher titres of
citramalate.
DISCUSSION
The reproducible, high titre production of citramalate (sum-
marized in Table 2) was demonstrated using a metabolically
engineered E. coli strain as the biocatalyst. The strain engi-
neering was beguilingly simple, since expression of
CimA3.7 coupled with only two knockouts was sufficient to
divert acetyl-CoA and pyruvate flux efficiently towards cit-
ramalate production when E. coli JW1 was used in a fed-
batch process with a continuous, limiting glucose feed.
Thus, product titres of 82 g l 1 were obtained reproducibly
over 65 h, with a productivity of 1.85 g l 1 h 1 and a conver-
sion efficiency of 0.48 gcitramalate g
 1
glucose.
In part, this efficiency was due to the channelling of the cen-
tral metabolic intermediates, pyruvate and acetyl-CoA,
directly towards the formation of the naturally occurring
intermediate, citramalate, in a single enzymatic step. Similar
efficiencies are obtained in other bioprocesses where the
chemical products are naturally occurring metabolites
formed from central intermediates (e.g. the succinate, cit-
rate, itaconate, poly-b-hydroxybutryrate and biobutanol
fermentations) [36]. Our study indicates that there is con-
siderable potential to develop this approach further, to pro-
duce a wider range of precursors for platform chemicals and
monomers, or chiral starting materials for chemical
synthesis.
Process efficiency was further enhanced by designing the
production strain and the bioprocess to work synergistically
together, so that acetate production could be avoided. This
approach made it unnecessary to delete any of the genes
involved in acetate production, so that there was no need to
add large quantities of expensive nutritional supplements
(glutamate or peptone) to overcome the auxotrophy created
by deletion of gltA [15, 16]. Furthermore, citraconate was
formed as a very minor co-product, and can be used as a
substrate for MAA production in the hot water process,
thus overcoming the need to delete leuC, and avoiding the
need for costly leucine supplementation. Thus, our strain
and process produced 50% more citramalate in only 75%
of the time compared with previous processes [15, 16], and
without formation of acetate as a co-product.
Although it appears that the citramalate yields (0.48 gcitrama-
late g
 1
glucose) are lower than in previous reports (0.64 gcitra-
malate g
 1
glucose) [15, 16], the latter studies involved the use
of media supplemented either with substantial quantities of
glutamate (25 g l 1) and leucine (5 g l 1) [16] or with pep-
tone (15 g l 1) [15]. These nutrients can be incorporated
directly into cell biomass, or used as energy sources, thus
reducing the amount of glucose needed to sustain growth,
and increasing the availability of glucose for citramalate
production. The authors did not measure or account for the
consumption of these additional nutrients, and calculated
the yield of citramalate based on glucose consumption
alone. Therefore, the apparent yields reported previously
[15, 16] are likely to be substantial over-estimates. By con-
trast, the yields determined in our study are reasonable esti-
mates of the true product yield on glucose, since the yeast
extract supplement added to the cultures represented <1%
of the total carbon-containing substrates added to the cul-
tures (i.e. the overall quantity of glucose fed was 172±11 g
l 1 compared with 1.4 g l 1 yeast extract).
In conclusion, the patented process [14] for citramalate pro-
duction provides the highest product titres reported to date,
with excellent productivities. Product yields represent 58%
of the theoretical maximum and the process does not need
expensive nutritional supplements to be added to the cul-
tures. Therefore, the patented process represents a much
more cost-effective system for citramalate production than
the processes reported subsequently [15, 16], and provides a
more attractive option for sustainable MAA manufacturing
through a combined biological and chemical route. Such
cost effectiveness is critical for bio-production of platform
Table 2. Comparison of fermentation processes for citramalate production
Fermentation Citramalate titre (g l 1) Fermentation length (h) Conversion efficiency
g g 1 mol mol 1
Batch-wise glucose addition (Fig. 2) 44* 63 0.43 0.53
Continuous glucose feed (Fig. 3) 82±1.5 65 0.48±0.03 0.58±0.03
Wu and Eiteman [13] 46.5 132 0.63† 0.76†
Parimi et al. [14] 54.1 87 0.64† 0.78†
*Maximum titre detected.
†Product yields are over-estimates, since the conversion of glutamate, leucine or peptone to citramalate was not measured.
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chemicals and monomers, due to the relatively low value of
the end products.
The availability of the high titre, high yield bioprocess
would also make citramalate an attractive bio-based precur-
sor to manufacture other, previously inaccessible products
with much higher values. Thus, citramalate has been used as
a chiral synthon for preparation of chiral aliphatic sul-
phones [37], and for isoprenoid synthesis [38], but these
processes have previously been limited by the high cost and
limited availability of enantiopure citramalate. The further,
deliberate conversion of citramalate to citraconic acid [12,
30–32, 39–41] may also have potential to provide a novel
C5 building block/monomer. Therefore, the bioprocess for
citramalate production has considerable future potential to
manufacture methacrylate monomers and high value
intermediates.
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